Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 21, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Transaction Date | Instrument | Price per ADS | Total Volume |
|---|---|---|---|
| July 20, 2017 | GSK American Depositary Shares (ADSs) | $42.8125 | 1,721.195 ADSs |
Note: Total volume is the aggregate of three separate transactions executed at the same price.
Material Changes
This filing does not report material changes to the company's financial position or operations compared to prior periods. It details routine acquisitions of ADSs by three executives following the re-investment of dividends paid on July 13, 2017.
Management Commentary and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The transactions were executed on the New York Stock Exchange (XNYS) and are classified as initial notifications.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ADSs resulting from dividend re-investment plans, not open market purchases.
- Executives Involved:
- Mr. N. Hirons (SVP, Global Ethics & Compliance): 16.250 ADSs
- Mr. B. McNamara (CEO, Consumer Healthcare): 192.536 ADSs
- Mr. D. E. Troy (SVP & General Counsel): 1,512.409 ADSs
- Execution Details: All trades occurred on July 20, 2017, at a uniform price of $42.8125 per ADS.
- Financial Data: No revenue, earnings, or balance sheet data is included in this specific filing.